[Transcatheter approach of concomitant mitral and tricuspid regurgitation]

G Ital Cardiol (Rome). 2021 Sep;22(9 Suppl 1):9S-20S. doi: 10.1714/3675.36612.
[Article in Italian]

Abstract

Severe mitral regurgitation represents the second most common indication for valve surgery in Europe. In the last decade, transcatheter mitral valve repair has become an established effective and safe treatment option for patients at high or prohibitive operative risk. A relevant proportion of these patients develop significant tricuspid regurgitation. Once considered a benign and reversible finding, nowadays increasing attention is being paid to the coexistence of this valvular disease, as a growing body of evidence points towards its negative prognostic role. Over the last few years, transcatheter repair has been performed successfully also for the treatment of significant tricuspid regurgitation in patients at high surgical risk. Therefore, combined transcatheter repair is emerging as a treatment strategy for high surgical risk patients with both severe mitral and tricuspid regurgitation. In this review, we provide a comprehensive summary of the epidemiology, pathophysiology, and prognostic role of the coexistence of severe mitral and tricuspid regurgitation. We then discuss the evidence in favor of combined surgical treatment and the emerging data supporting combined transcatheter treatment, with attention to available treatment technologies. The paper is further enriched with three practical case reports and with the suggestion of a decision-making algorithm for the management of this complex subset of patients.

Publication types

  • Review

MeSH terms

  • Cardiac Catheterization
  • Cardiac Surgical Procedures*
  • Europe
  • Heart Valve Prosthesis Implantation*
  • Humans
  • Mitral Valve Insufficiency* / epidemiology
  • Mitral Valve Insufficiency* / surgery
  • Treatment Outcome
  • Tricuspid Valve / surgery
  • Tricuspid Valve Insufficiency* / surgery